نتائج البحث - "Zvonko, Milicevic"

1

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

المؤلفون: Ross Bray, Amir Nikooienejad, Deborah A. Robins, Axel Haupt, Kevin L. Duffin, Jonathan M. Wilson, Melissa K. Thomas, Zvonko Milicevic, Xuewei Cui

المصدر: The Journal of Clinical Endocrinology and Metabolism

مصطلحات موضوعية: Blood Glucose, Male, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Clinical Biochemistry, Type 2 diabetes, Biochemistry, Endocrinology, Insulin-Secreting Cells, Medicine, Proinsulin, GIP, Middle Aged, Prognosis, Homeostatic model assessment, Female, type 2 diabetes, AcademicSubjects/MED00250, medicine.drug, Adult, medicine.medical_specialty, Adolescent, tirzepatide, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1 Receptor, Young Adult, Insulin resistance, Clinical Trials, Phase II as Topic, Internal medicine, insulin sensitivity, Humans, Hypoglycemic Agents, Glucagon-like peptide 1 receptor, Clinical Research Articles, Aged, Glycated Hemoglobin, Adiponectin, business.industry, beta-cell function, Insulin, Biochemistry (medical), medicine.disease, Diabetes Mellitus, Type 2, Dulaglutide, Insulin Resistance, business, GLP-1, Biomarkers, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6320a46b48d64dfafd5061c85da73165Test
http://europepmc.org/articles/PMC7823251Test

2

Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial

المؤلفون: Zvonko Milicevic, Francesco Giorgino, Luis-Emilio Garcia-Perez, Maria Yu, Axel Haupt

المصدر: Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Agonist, Blood Glucose, Male, medicine.medical_specialty, medicine.drug_class, Endocrinology, Diabetes and Metabolism, Recombinant Fusion Proteins, Glucagon-Like Peptides, Insulin Glargine, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Glucagon, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Post-hoc analysis, dulaglutide, Weight Loss, Internal Medicine, Medicine, Humans, Hypoglycemic Agents, basal insulin, Aged, Glycated Hemoglobin, business.industry, Insulin glargine, Brief Report, Middle Aged, medicine.disease, Postprandial Period, Immunoglobulin Fc Fragments, Clinical trial, Postprandial, Diabetes Mellitus, Type 2, Dulaglutide, Brief Reports, Female, sense organs, type 2 diabetes, business, GLP‐1, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bec5936ad72f840f15dced712c732323Test
http://europepmc.org/articles/PMC6852007Test

3

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

المؤلفون: Lai S. Tham, Ying G. Li, Dagmar Bartaskova, Zvonko Milicevic, Brad Woodward, David A. Cox, Juan P. Frias, Alan G. Wynne, Beata Matyjaszek-Matuszek

المصدر: Diabetes, Obesity and Metabolism. 21:2048-2057

مصطلحات موضوعية: Adult, Blood Glucose, Male, medicine.medical_specialty, Nausea, Recombinant Fusion Proteins, Endocrinology, Diabetes and Metabolism, Glucagon-Like Peptides, Urology, Placebo-controlled study, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, 03 medical and health sciences, Subcutaneous injection, 0302 clinical medicine, Endocrinology, Double-Blind Method, Weight loss, Weight Loss, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Aged, Glycated Hemoglobin, business.industry, Middle Aged, medicine.disease, Metformin, Immunoglobulin Fc Fragments, Treatment Outcome, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Dulaglutide, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbb56e6e05c0c6bbde72032bfb9c14cTest
https://doi.org/10.1111/dom.13764Test

4

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

المؤلفون: Shweta Urva, Ruth E. Gimeno, Mark E Kutner, Michael A. Nauck, Axel Haupt, Joanna Van, Zvonko Milicevic, Charles Benson, Juan P. Frias, Deborah A. Robins, Xuewei Cui

المصدر: Lancet (London, England). 392(10160)

مصطلحات موضوعية: 0301 basic medicine, Blood Glucose, Male, medicine.medical_specialty, Recombinant Fusion Proteins, Population, Glucagon-Like Peptides, 030209 endocrinology & metabolism, Type 2 diabetes, Gastric Inhibitory Polypeptide, Placebo, Gastroenterology, Drug Administration Schedule, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Weight loss, Internal medicine, Diabetes mellitus, Weight Loss, medicine, Humans, Hypoglycemic Agents, education, Glycated Hemoglobin, education.field_of_study, business.industry, General Medicine, Middle Aged, medicine.disease, Metformin, Immunoglobulin Fc Fragments, 030104 developmental biology, Treatment Outcome, Tolerability, Diabetes Mellitus, Type 2, Dulaglutide, Female, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010e846962f8f8c5b018a7f53d736ddeTest
https://pubmed.ncbi.nlm.nih.gov/30377302Test

5

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

المؤلفون: Francisco J. Tinahones, Juan P. Frias, Honghua Jiang, Luis-Emilio Garcia-Perez, Zvonko Milicevic, Julio Wainstein, D. Bradley Woodward, Kenneth E. Robertson, Bernhard Ludvik

المصدر: The lancet. Diabetesendocrinology. 6(5)

مصطلحات موضوعية: Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Recombinant Fusion Proteins, Population, Placebo-controlled study, Glucagon-Like Peptides, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, education, Sodium-Glucose Transporter 2 Inhibitors, Glycated Hemoglobin, education.field_of_study, business.industry, Middle Aged, medicine.disease, Metformin, Immunoglobulin Fc Fragments, Treatment Outcome, Tolerability, Diabetes Mellitus, Type 2, Dulaglutide, Drug Therapy, Combination, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98bc6b8a2e50aeaa553a9cad2fcb51dfTest
https://pubmed.ncbi.nlm.nih.gov/29803266Test

6

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

المؤلفون: Lawrence Blonde, Honghua Jiang, Jessie L. Fahrbach, Zvonko Milicevic, Jorge Luiz Gross, Vincent Woo, Johan Jendle

المصدر: The Lancet. 385:2057-2066

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Adolescent, Recombinant Fusion Proteins, medicine.medical_treatment, Glucagon-Like Peptides, Insulin Glargine, Type 2 diabetes, Bedtime, Drug Administration Schedule, law.invention, Young Adult, Randomized controlled trial, law, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Aged, Glycated Hemoglobin, Insulin Lispro, Intention-to-treat analysis, Insulin glargine, business.industry, Insulin, General Medicine, Middle Aged, Postprandial Period, medicine.disease, Immunoglobulin Fc Fragments, Surgery, Insulin, Long-Acting, Treatment Outcome, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Dulaglutide, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db9ae694e7f70fa658ac922998e28665Test
https://doi.org/10.1016/s0140-6736Test(15)60936-9

7

Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)

المؤلفون: Kristina S. Boye, Zvonko Milicevic, Oralee J. Varnado, Kate Van Brunt, Maria Yu

المصدر: Clinical therapeutics. 39(11)

مصطلحات موضوعية: Blood Glucose, Male, medicine.medical_specialty, Recombinant Fusion Proteins, Glucagon-Like Peptides, Insulin Glargine, 030209 endocrinology & metabolism, Type 2 diabetes, Placebo, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Double-Blind Method, Diabetes mellitus, Internal medicine, medicine, Humans, Hypoglycemic Agents, Pharmacology (medical), 030212 general & internal medicine, Patient Reported Outcome Measures, Aged, Pharmacology, Glycated Hemoglobin, Insulin glargine, business.industry, Body Weight, Repeated measures design, Middle Aged, medicine.disease, Metformin, Surgery, Immunoglobulin Fc Fragments, Diabetes Mellitus, Type 2, Quality of Life, Dulaglutide, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8004f9f2154bc53e780a06cd05594b67Test
https://pubmed.ncbi.nlm.nih.gov/29110972Test

8

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

المؤلفون: Honghua Jiang, Tibor Ivanyi, Zvonko Milicevic, Paolo Pozzilli, D. Bradley Woodward, Melanie J. Davies, Esteban Jódar, Paul Norwood

المصدر: ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)

مصطلحات موضوعية: Male, Endocrinology, Diabetes and Metabolism, Drug Resistance, Glucagon-Like Peptides, Insulin Glargine, Type 2 diabetes, Gastroenterology, law.invention, Tratamiento médico, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Insulina, 030212 general & internal medicine, Middle Aged, Metformin, Intention to Treat Analysis, Sistema endocrino, Anesthesia, Drug Therapy, Combination, Female, medicine.symptom, Drug Monitoring, medicine.drug, medicine.medical_specialty, Patient Dropouts, Nausea, Injections, Subcutaneous, Recombinant Fusion Proteins, 030209 endocrinology & metabolism, Placebo, Incretins, Drug Administration Schedule, Glucagon-Like Peptide-1 Receptor, Diabetes tipo 2, 03 medical and health sciences, Double-Blind Method, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Glucagon-like peptide 1 receptor, Aged, Glycated Hemoglobin, business.industry, Insulin glargine, medicine.disease, Hypoglycemia, Immunoglobulin Fc Fragments, Diabetes Mellitus, Type 2, Hyperglycemia, Dulaglutide, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb860e15a9a9b63f019cdaef31d2dddfTest
https://pubmed.ncbi.nlm.nih.gov/28294499Test

9

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

المؤلفون: Jamie S. Barkin, Greg Anglin, Zvonko Milicevic, Ingrid E. Hensley, Kristine D. Harper, Jean-Louis Frossard, Michael A. Nauck

المصدر: Diabetes care. 40(5)

مصطلحات موضوعية: Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Recombinant Fusion Proteins, Glucagon-Like Peptides, Insulin Glargine, 030209 endocrinology & metabolism, Placebo, Gastroenterology, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, 030212 general & internal medicine, Advanced and Specialized Nursing, Insulin glargine, business.industry, Venoms, Sitagliptin Phosphate, Middle Aged, medicine.disease, Metformin, Surgery, Immunoglobulin Fc Fragments, Diabetes Mellitus, Type 2, Pancreatitis, Sitagliptin, Acute Disease, Acute pancreatitis, Exenatide, Dulaglutide, Female, business, Peptides, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::478369b0afe64c4d103646bbb1cc0d50Test
https://pubmed.ncbi.nlm.nih.gov/28283565Test

10

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy

المؤلفون: Sherry Martin, Marcia A. Testa, Zvonko Milicevic, Johan Jendle, Honghua Jiang

المصدر: Diabetes, obesitymetabolism. 18(10)

مصطلحات موضوعية: Blood Glucose, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Recombinant Fusion Proteins, Urology, Glucagon-Like Peptides, Insulin Glargine, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, In patient, Meals, Glucagon-like peptide 1 receptor, Aged, Insulin Lispro, business.industry, Continuous glucose monitoring, Insulin, Blood Glucose Self-Monitoring, Middle Aged, medicine.disease, Immunoglobulin Fc Fragments, Regimen, Diabetes Mellitus, Type 2, Dulaglutide, Drug Therapy, Combination, Female, business, Prandial insulin, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc46469b6a75cf254fbaa087eb7848fTest
https://pubmed.ncbi.nlm.nih.gov/27279266Test

تنقيح النتائج